Compass Therapeutics stock plunges on trial data concerns, William Blair comments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
H.C. Wainwright on Compass Therapeutics (CMPX): 'we do believe the probability of a path forward is meaningfully higher than the market reaction observed'
April 27, 2026 11:50 AM EDTH.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $24.00 price target on Compass Therapeutics (NASDAQ: CMPX)
The analyst comments "What's next? The key question remains whether the FDA will accept PFS as the approvability anchor, along with the previously established ORR, or whether is will require OS. As the post-hoc non-crossover OS analysis was not pre-specified, the FDA may potentially scrutinize its usage.... More
Leerink on Compass Therapeutics (CMPX): 'there are multiple sources of long-term upside'
April 27, 2026 10:20 AM EDTLeerink Partners analyst Andrew Berens reiterated an Outperform rating and $11.00 price target on Compass Therapeutics (NASDAQ: CMPX).
The analyst comments "CMPX announced PFS and OS results for tovecimig in 2L BTC from the randomized COMPANION-002 study. At a high level, we view this data update as supportive of a path forward in an area of high unmet need. Recall, CMPX is evaluating tovecimig (CTX-009, DLL4xVEGF-A bispecific) + paclitaxel vs. paclitaxel in the Phase II/III COMPANION-002 study for 2L biliary tract cancer (BTC). In April 2025, CMPX announced that the study has met its... More
Stifel on Compass Therapeutics (CMPX): 'Path Forward Complicated by FDA’s “Imply-No-Harm” Mandate'
April 27, 2026 8:27 AM EDTStifel analyst Stephen Willey reiterated a Buy rating and $12.00 price target on Compass Therapeutics (NASDAQ: CMPX).
The analysdt comments "Secondary endpoint data from the P2/3 COMPANION-002 trial (paclitaxel ± tovecimig, 2L BTC) establishes a statistically-significant/clinicallymeaningful tovecimig-mediated improvement in mPFS (4.7 vs. 2.6 months, HR=0.44).... More
